These insights significantly contribute to the expansion of CAR T-cell therapy for ovarian cancer by pinpointing UBE2C and its associated molecular pathways as promising therapeutic targets, potentially enhancing the precision and effectiveness of these innovative treatments in managing a malignancy notorious for its grim prognosis and limited therapeutic options [79]. This evidence concerns the gene UBE2C and ovarian cancer.